Relevance of FRASER Kremer cohort known pathogenic-event subsampling to "Select a patient-RNA splicing-variant validation workflow"
- Use case
- Select a patient-RNA splicing-variant validation workflow
- Assessed by
- FRASER Kremer cohort known pathogenic-event subsampling
- Relevance
- Direct evidence
- Endpoint
- Mean recovery of 13 known pathogenic splicing events at reduced cohort size (30 of 119 patient RNA samples) using FRASER on patient skin-fibroblast RNA
Direct patient-RNA evidence measuring recovery of known pathogenic splicing events bears on the declared decision, scoped narrowly to known-event recovery rather than diagnostic yield in unknown cases.
1 reviewed evaluation
Evidence
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Evidence table
Inspect claims, sources and review details
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
15 evidence rows matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|---|---|
Citation locations1 values
| Detection of aberrant splicing events in RNA-seq data using FRASER amp-oncology-rna-20261007-source-pmc7822922: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/ Version: Europe PMC fullTextXML retrieved 2026-10-07T12:23:57.289375+00:00 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
Constraints2 values
| Detection of aberrant splicing events in RNA-seq data using FRASER amp-oncology-rna-20261007-source-pmc7822922: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/ Version: Europe PMC fullTextXML retrieved 2026-10-07T12:23:57.289375+00:00 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Endpoint Mean recovery of 13 known pathogenic splicing events at reduced cohort size (30 of 119 patient RNA samples) using FRASER on patient skin-fibroblast RNA Context-only references | Detection of aberrant splicing events in RNA-seq data using FRASER amp-oncology-rna-20261007-source-pmc7822922: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/ Version: Europe PMC fullTextXML retrieved 2026-10-07T12:23:57.289375+00:00 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Claimed field links:assessed_by:amp-oncology-rna-20261007-protocol-fraser-kremer-subsampling Context-only references | Detection of aberrant splicing events in RNA-seq data using FRASER amp-oncology-rna-20261007-source-pmc7822922: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/ Version: Europe PMC fullTextXML retrieved 2026-10-07T12:23:57.289375+00:00 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
Limitations6 values
| Detection of aberrant splicing events in RNA-seq data using FRASER amp-oncology-rna-20261007-source-pmc7822922: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/ Version: Europe PMC fullTextXML retrieved 2026-10-07T12:23:57.289375+00:00 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
Pinned records6 values
| Detection of aberrant splicing events in RNA-seq data using FRASER amp-oncology-rna-20261007-source-pmc7822922: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/ Version: Europe PMC fullTextXML retrieved 2026-10-07T12:23:57.289375+00:00 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Rationale Direct patient-RNA evidence measuring recovery of known pathogenic splicing events bears on the declared decision, scoped narrowly to known-event recovery rather than diagnostic yield in unknown cases. Context-only references | Detection of aberrant splicing events in RNA-seq data using FRASER amp-oncology-rna-20261007-source-pmc7822922: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/ Version: Europe PMC fullTextXML retrieved 2026-10-07T12:23:57.289375+00:00 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Reason Add Codex-checked primary-source protocol evidence from the bounded AMP intake (rewire.it#365). Context-only references | Detection of aberrant splicing events in RNA-seq data using FRASER amp-oncology-rna-20261007-source-pmc7822922: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/ Version: Europe PMC fullTextXML retrieved 2026-10-07T12:23:57.289375+00:00 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Relevance direct Context-only references | Detection of aberrant splicing events in RNA-seq data using FRASER amp-oncology-rna-20261007-source-pmc7822922: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/ Version: Europe PMC fullTextXML retrieved 2026-10-07T12:23:57.289375+00:00 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Revision 1 Context-only references | Detection of aberrant splicing events in RNA-seq data using FRASER amp-oncology-rna-20261007-source-pmc7822922: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/ Version: Europe PMC fullTextXML retrieved 2026-10-07T12:23:57.289375+00:00 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
Sources and history
Release 2026-11-21-c8bea25e5abb · Record review: source checked
1 source record and release history
- Detection of aberrant splicing events in RNA-seq data using FRASER · Original source · Europe PMC fullTextXML retrieved 2026-10-07T12:23:57.289375+00:00
Technical metadata and extraction receipts
Stable ID: use-case-mapping-amp-20261007-issue12-fraser-kremer
- field
- links:assessed_by:amp-oncology-rna-20261007-protocol-fraser-kremer-subsampling
- value
- amp-oncology-rna-20261007-protocol-fraser-kremer-subsampling
- relevance
- direct
- endpoint
- Mean recovery of 13 known pathogenic splicing events at reduced cohort size (30 of 119 patient RNA samples) using FRASER on patient skin-fibroblast RNA
- rationale
- Direct patient-RNA evidence measuring recovery of known pathogenic splicing events bears on the declared decision, scoped narrowly to known-event recovery rather than diagnostic yield in unknown cases.
- constraints
- Inspect every linked evaluation's source locator and preserved conflicts before citing a result.; Do not combine this mapping's evaluations with any other protocol's results.
- limitations
- Direct patient-RNA known-event recovery does not establish prospective diagnostic accuracy or patient outcome benefit.; Known pathogenic-event ascertainment and same-cohort retrospective selection can bias recovery.; 30 is RNA sample subset size; do not silently equate to 30 independent patients.; No blinded pathogenicity adjudication, general tissue transfer, VUS reclassification sensitivity or transcriptome-wide precision established by this endpoint.; Subsampling repeats, exact score aggregation and numeric uncertainty unavailable from inspected main-text endpoint; supplementary PDF DNS retrieval failed.; FRASER author correction 2022 changes GTEx version V7 to V6p; patient-Kremer endpoint not affected according to correction search result; exact correction bytes not retrieved.
- revision
- 1
- reason
- Add Codex-checked primary-source protocol evidence from the bounded AMP intake (rewire.it#365).
- citation locators
- source id: amp-oncology-rna-20261007-source-pmc7822922; locator: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/
- source locator
- amp-oncology-rna-20261007-source-pmc7822922: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/
- review
- method: automated-source-review; reviewer: codex; claude-sonnet; reviewer note: Claude Sonnet AMP-integration worker, bounded transcription of Codex-checked primary values; independently reviewed by Codex (workbench/amp-supervision/primary-review.md, integration-review-corrections.md); reviewed at: 2026-10-07T13:38:59Z; note: Bounded primary-source transcription, independently Codex-checked. No new model execution, independent experimental reproduction, qualified human scientific review or clinical validation.
- reviewed evaluations
- amp-oncology-rna-20261007-issue-12-eval-fraser-2021-article-implementation
- pins
- record id: amp-oncology-rna-20261007-issue-12-eval-fraser-2021-article-implementation; fields: status; links; attributes.origin; attributes.comparison; sha256: 8963c6759c168523575320048ab0de94c29b970a518d286c460900bbf242d5df; record id: amp-oncology-rna-20261007-issue-12-result-fraser-2021-article-implementation-mean-known-pathogenic-splicing-event-recovery-at-30-samples; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 83f4893f9f5db344c117dc78f108dbad3f029ed3927810a596a0f79196ef482f; record id: amp-oncology-rna-20261007-issue-12-result-fraser-2021-article-implementation-mean-recovered-known-pathogenic-events-at-30-samples; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 8c7f2485c97609edc56e1f0664b675079213a745afe99b5bf3fd98c78c04678e; record id: amp-oncology-rna-20261007-protocol-fraser-kremer-subsampling; fields: status; name; description; facets; source_ids; links; attributes; sha256: 366c7dc5c429175eb4f89e57c2e8189e063366498e4d4d4f57b6ccd8d959a5ea; record id: amp-oncology-rna-20261007-source-pmc7822922; fields: status; attributes.artifact_sha256; sha256: bd7e82c3608d41aa8da0e2a6c2053e5ba1f5cae0a4ed9b0e3dbd853e2965d8cc; record id: use-case-patient-rna-splicing-validation; fields: status; name; description; facets; attributes.question; attributes.decision; attributes.inputs; attributes.output; attributes.exclusions; attributes.setting; attributes.clinical_scope; attributes.intended_users; sha256: b85cad56e15fbfad66a2e70c3b193ed56c464e5e44b62a19b12f391e409ec897